Category - Markets

Markets

Dawson James starts Genprex at buy; PT $3

Dawson James Securities initiated coverage of Genprex (NASDAQ:GNPX) with a “buy” rating and $3 price target. The stock closed at $1.34 on Jan. 27. Genprex is a clinical-stage gene therapy company pioneering the...

January 30, 2023

Markets

Stifel starts Compass Therapeutics at buy; PT $9

Stifel initiated coverage of Compass Therapeutics (NASDAQ:CMPX) with a “buy” rating and price target of $9. The stock closed at $3.95 on Jan. 26. “We believe the recent presentation at ASCO-GI 2023 of updated results...

January 27, 2023

Markets

AGP drops coverage of Viveve Medical after failed Phase 3 trial

Alliance Global Partners dropped coverage of Vivere Medical (NASDAQ:VIVE) after its pivotal PURSUIT trial in stress urinary incontinence (SUI) in women did not meet its primary endpoint nor several secondary endpoints...

January 23, 2023

Markets

Dawson James starts Zomedica at buy; PT $6

Dawson James initiated coverage of Zomedica (NYSEA:ZOM) with a “buy” rating and price target of $6. The stock closed at 20 cents on Jan. 5. Analyst Jason Kolbert writes that Zomedica is positioning itself as a leading...

January 6, 2023

Markets

Stifel ups Sight Sciences to buy after survey

Stifel upgraded Sight Sciences (NASDAQ:SGHT) to “buy” from “ hold” and raised its price target to $15 from $10 after a survey of 41 minimally invasive glaucoma surgery (MIGS)-trained ophthalmologists “gives us increased...

January 6, 2023

Markets

Cantor resumes coverage of Nano-X Imaging at OW; PT $21

Cantor Fitzgerald resumed coverage of Nano-X Imaging (NASDAQ:NNOX) with an “overweight” rating and 12-month price target of $21 after attending the company’s ARC Day in Israel. The stock closed at $7.60 on Jan. 4. The...

January 5, 2023

Markets

HCW starts Poseida Therapeutics at buy; PT $15

H.C. Wainwright initiated coverage of Poseida Therapeutics (NASDAQ:PSTX) with a “buy” rating and $15 price target. The stock closed at $5.79 on Jan. 2. Poseida is a clinical-stage biopharmaceutical company focused on...

January 4, 2023

Markets

Raymond James ups Quipt Home Medical PT after acquisition

Raymond James raised its price target for Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) to $14 from $10, and reiterated its “outperform” rating after the company acquired Great Elm Healthcare for about $80-million. The...

January 4, 2023

Markets

BTIG starts Sophia Genetics at buy; PT $6

BTIG initiated coverage of Sophia Genetics (NASDAQ:SOPH) with a “buy” rating and $6 price target. The stock price closed at $2.06 on Dec. 30. Sophia is a rapidly growing, global healthcare technology company that sells...

January 3, 2023

Markets

Cantor ups Ardelyx PT to $3 after FDA update

Cantor Fitzgerald raised its price target for Ardelyx (NASDAQ:ARDX) to $3 from $1.60 but maintained a “neutral” rating after a label update from the FDA. The stock closed at $2.51 on Dec. 28. Ardelyx announced that the...

December 29, 2022

Category - Markets

Subscribe